

Information notice of March 29, 2016

## BB Biotech: 5-for-1 share split completed

After receiving shareholder approval at the Annual General Meeting on March 17, 2016, the 5-for-1 share split was effected on March 29, 2016. The share split reduced the share price to one-fifth of the previous closing price while the number of outstanding registered shares rose to 59,250,000, each with a par value of CHF 0.20, and the overall amount of share capital remained unchanged.

Splitting the par value per share should increase the stock's liquidity and tradability.

### More information

Verhältnis	5-for-1, meaning 1 registered share with a par value of CHF 1.00 will be splitted into 5 registered shares with a par value of CHF 0.20 each.
Ex-Date	March 29, 2016
Record Date	March 30, 2016
Closing date	March 31, 2016

### Investor Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00

Dr. Silvia Schanz, ssc@bellevue.ch

Maria-Grazia Iten-Alderuccio, mga@bellevue.ch

Claude Mikkelsen, cmi@bellevue.ch

**[www.bbbiotech.com](http://www.bbbiotech.com)**

### Company profile

BB BIOTECH invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

### Disclaimer

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.